Molecular basis of ligand binding and receptor activation at the human A3 adenosine receptor

Liudi Zhang, Jesse I. Mobbs, Felix M. Bennetts, Hariprasad Venugopal, Anh T. N. Nguyen, Arthur Christopoulos, Daan van der Es, Laura H. Heitman, Lauren T. May (), Alisa Glukhova () and David M. Thal ()
Additional contact information
Liudi Zhang: Monash Institute of Pharmaceutical Sciences, Monash University
Jesse I. Mobbs: Monash Institute of Pharmaceutical Sciences, Monash University
Felix M. Bennetts: Monash Institute of Pharmaceutical Sciences, Monash University
Hariprasad Venugopal: Monash University
Anh T. N. Nguyen: Monash Institute of Pharmaceutical Sciences, Monash University
Arthur Christopoulos: Monash Institute of Pharmaceutical Sciences, Monash University
Daan van der Es: Leiden Academic Centre for Drug Research, Leiden University
Laura H. Heitman: Leiden Academic Centre for Drug Research, Leiden University
Lauren T. May: Monash Institute of Pharmaceutical Sciences, Monash University
Alisa Glukhova: Monash Institute of Pharmaceutical Sciences, Monash University
David M. Thal: Monash Institute of Pharmaceutical Sciences, Monash University

Nature Communications, 2025, vol. 16, issue 1, 1-19

Abstract: Abstract Adenosine receptors (ARs: A1AR, A2AAR, A2BAR, and A3AR) are crucial therapeutic targets; however, developing selective, efficacious drugs for them remains a significant challenge. Here, we present high-resolution cryo-electron microscopy (cryo-EM) structures of the human A3AR in three distinct functional states: bound to the endogenous agonist adenosine, the clinically relevant agonist Piclidenoson, and the covalent antagonist LUF7602. These structures, complemented by mutagenesis and pharmacological studies, reveal an A3AR activation mechanism that involves an extensive hydrogen bond network from the extracellular surface down to the orthosteric binding site. In addition, we identify a cryptic pocket that accommodates the N6-iodobenzyl group of Piclidenoson through a ligand-dependent conformational change of M1745.35. Our comprehensive structural and functional characterisation of A3AR advances our understanding of adenosine receptor pharmacology and establishes a foundation for developing more selective therapeutics for various disorders, including inflammatory diseases, cancer, and glaucoma.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-62872-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-62872-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-62872-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().